Role of combined mucolytic therapy in infectious and inflammatory diseases of the respiratory system in children
https://doi.org/10.21518/2079-701X-2019-11-56-59
Abstract
The use of combined medicines simultaneously influencing various pathogenetic mechanisms of inflammation and coughing becomes an essential direction of mucoactive therapy in childhood. One of these is thiamphenicol glycinate acetylcysteinate, which has both mucolytic and antibacterial effects, which significantly expands the possibilities of therapy in bacterial etiology of acute and exacerbation of chronic respiratory diseases, increases the effectiveness of therapeutic measures, improves compliance.
About the Authors
Yu. L. Mizernitsky
Separate business unit Research Clinical Institute of Pediatrics named after Academician Yu.E. Veltischev of the Federal State Educational Institution of Higher Education Russian National Research Medical University named after N.I. Pirogov of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Mizernitsky Yuri Leonidovich – Dr. of Sci. (Med), Professor, Honored Worker of Public Health of the Russian Federation, Head of the Department of Chronic Inflammatory and Allergic Pulmonary Diseases of the Separate business unit Research Clinical Institute of Pediatrics named after Academician Yu.E. Veltischev of the Federal State Educational Institution of Higher Education Russian National Research Medical University named after N.I. Pirogov of the Ministry of Health of the Russian Federation, Head of the Department of Chronic Inflammatory and Allergic Diseases of the Russian Federation
125412, Moscow, Taldomskaya Street, 2
I. M. Melnikova
Federal State Budgetary Educational Institution of Higher Education Yaroslavl State Medical University of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Melnikova Irina Mikhailovna – Dr. of Sci. (Med), Professor, Head of the Department of Hospital Pediatrics
150000, Yaroslavl, Revolutsionnaya St., 5
References
1. Geppe N.A., Dronov I.A., Kolosova N.G. Efficacy of use of thiamphenicol acetylcysteinate glycinate in acute bronchitis in children. RMZh. 2016;1:1-5. (In Russ.)
2. Zhakov Ya.I., Minina E.E., Babaylov M.S. Influence of lazolvan (ambroxol) on the dynamics of inflammatory process of bronchial mucosa after acute bronchitis in children according to induced sputum. RMZh. 2011;19(22):1361-1364. (In Russ.)
3. Kunelskaya N.L., Turovsky A.B., Izotova G.N. et al. Possibilities of inhalation application of combined preparations in treatment of acute sinusitis. Med. sovet. 2014;3:30-33. (In Russ.)
4. Melnikova I.M., Mizernitsky Yu.L., Batozhargalova B.C., Loginevskaya Ya.V. Modern principles of mucolytic therapy in children with acute and chronic bronchopulmonary diseases. Ros. vestn. perinatol. i pediatrii. 2011;56(2):4550. (In Russ.)
5. Melnikova I.M., Udaltsova E.V., Mizernitsky Yu.L. Algorithms of differential diagnostics of diseases accompanied by prolonged and chronic cough in children. Pediatriya. Zhurnal imeni G.N. Speranskogo. 2018;97(2):8-18. (In Russ.)
6. Mysernitsky Yu.L. Expectorant and mucolytic agents in therapy of bronchopulmonary diseases in children. Guidelines for pharmacotherapy in pediatrics and pediatric surgery. Under the editorship of A.D. Tsaregorodtsev, V.A. Tabolin. V.1 Pharmacotherapy in pediatric pulmonology. Under the editorship of S.Yu. Kaganova. Moscow: Medpraktika-M, 2002:123-140. (In Russ.)
7. Mizernitsky Yu.L., Melnikova I.M. Mucolytic and expectorant pharmacotherapy for lung diseases in children. Moscow: Medpraktika-M, 2013. 120 p. (In Russ.)
8. Mizernitskiy Yu.L., Melnikova I.M., Batozhargalova B.C. Place of acetylcysteine in modern mucolytic therapy in children with bronchopulmonary diseases. Praktika pediatra. October 2013: 30-33. (In Russ.)
9. Novikov Yu.K. Mucociliary transport as the main mechanism of lung protection. RMZh. 2007;15(5):357-360. (In Russ.)
10. Ovcharenko S.I., Kapustina V.A., Son E.A. Successful application of inhalation form of thiamphenicol glycine in complex therapy of infectious and inflammatory diseases of respiratory organs. Farmateka. 2010;11:42-45.] (In Russ.)
11. Postnikov S.S., Grazianskaya A.N. Inhalation therapy in respiratory infections: fluimucil antibiotic IT. Praktika pediatra. 2016;3:56-59 (In Russ.)
12. Rozinova N.N., Mizernitsky Yu.L. Chronic lung diseases in children. Moscow: Practice, 2011. 234 s. (In Russ.)
13. Savvina N.V., Uarova A.V. Modern inhalation therapy of acute respiratory tract diseases in children. Vopr. prakt. pediatrii. 2010;5(4):92-95. (In Russ.)
14. Soroka N.D., Smirnova N.N., Mikhailova O.V., Pechiborshch A.Z. Tiamphenicol glycinate acetylcysteinate (Fluimucil®-antibiotic IT) and its place in the treatment of respiratory diseases in childhood. Praktika pediatra. 2017;3:42-47. (In Russ.)
15. Chuchalin A.G., Abrosimov V.N. Cough. M.: GEOTAR-Media, 2016. 160 p. (In Russ.)
16. Aizawa H., Koarai A., Shishikura Y. et al. Oxidative stress enhances the expression of IL-33 in human airway epithelial cells. Respir Res. 2018;19(1):52.
17. Balli F., Bergamini B., Calistru P. et al. Clinical effects of erdosteine in the treatment of acute respiratory tract diseases in children. Int J Clin Pharmacol Ther., 2007;45(1):16-22.
18. Benedikter B.J., Volgers C., van Eijck P.H. et al. Cigarette smoke extract induced exosome release is mediated by depletion of exofacial thiols and can be inhibited by thiol-antioxidants. Free Radic Biol Med. 2017;108:334-344.
19. Blasi F., Page C., Rossolini G.M. et al. The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections. Respir Med. 2016;117:190-197.
20. Dinwiddie D.L., Denson J.L., Kennedy J.L. Role of the Airway Microbiome in Respiratory Infections and Asthma in Children. Pediatr Allergy Immunol Pulmonol. 2018;31(4):236-240.
21. Kantar A., Chang A.B., Shields M.D. et al. ERS statement on protracted bacterial bronchitis in children. Eur Respir J. 2017;50(2):pii 1602139.
22. Loscialpo Ramundo D. On the use of the association of acetylcysteine and thiamphenicol glycinate in some pediatric pulmonary diseases. Clin Pediatr (Bologna). 1968;50(2):43-56.
23. Macchi A., Ardito F., Marchese A., Schito G.C., Fadda G. Efficacy of N-acetylcysteine in combination with thiamphenicol in sequential (intramuscular/ aerosol) therapy of upper respiratory tract infections even when sustained by bacterial biofilms. J Chemother. 2006;18(5):507-513.
24. Macchi A., Castelnuovo P. Aerosol antibiotic therapy in children with chronic upper airway infections: a potential alternative to surgery. Int J Immunopathol Pharmacol. 2009;22(2):303-310.
25. Mayaud C., Lentschner C., Bouchoucha S., Marsac J. Thiamphenicol glycinate acetylcysteinate in the treatment of acute respiratory infections with mucostasis. J. Eur J Respir Dis. 1980;111(Suppl):70-73.
26. Millea P.J. N-acetylcysteine: multiple clinical applications. Am Fam Physician. 2009;80(3):265-269.
27. Naz F., Raza A.B., Ijaz I., Kazi M.Y. Effectiveness of nebulized N-acetylcysteine solution in children with acute bronchiolitis. J Coll Physicians Surg Pak. 2014;24(6):408-411.
28. Pappova L., Kazimierova I., Joškova M. et al. Acute and chronic effects of oral erdosteine on ciliary beat frequency, cough sensitivity and airway reactivity. Adv Exp Med Biol. 2018;1023:1-10.
29. Rubin B.K. Aerosol medications for treatment of mucus clearance disorders. Respir Care. 2015;60(6):825-829.
30. Serra A., Schito G.C., Nicoletti G., Fadda G. A therapeutic approach in the treatment of infections of the upper airways: thiamphenicol glycinate acetylcysteinate in sequential treatment (systemic-inhalatory route). Int J Immunopathol Pharmacol. 2007;20(3):607-617.
31. Unger S.A., Bogaert D. The respiratory microbiome and respiratory infections. J Infect. 2017;74(Suppl 1):S84-S88.
32. Varelogianni G., Oliynyk I., Roomans G.M., Johannesson M. The effect of N-acetylcysteine on chloride efflux from airway epithelial cells. Cell Biol Int. 2010;34(3):245-252.
33. Vukosavljevic B., Murgia X., Schwarzkopf K. et al. Tracing molecular and structural changes upon mucolysis with N-acetyl cysteine in human airway mucus. Int J Pharm. 2017;533(2):373-376.
Review
For citations:
Mizernitsky YL, Melnikova IM. Role of combined mucolytic therapy in infectious and inflammatory diseases of the respiratory system in children. Meditsinskiy sovet = Medical Council. 2019;(11):56-59. (In Russ.) https://doi.org/10.21518/2079-701X-2019-11-56-59
Views:
834
Email this article 